Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Literatur:

Die Diagnostik des Lungenkarzinoms

J. Ficker, Nürnberg (Seite 10)

 

  1. National Cancer Institute. Seer Cancer Statistics.
  2. Goeckenjan, G. et al. Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie 65, 39–59 (2011).
  3. Field, J. K., Devaraj, A., Duffy, S. W. & Baldwin, D. R. CT screening for lung cancer: Is the evidence strong enough? Lung Cancer 91, 29–35 (2016).
  4. Navani, N. et al. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. The Lancet Respiratory Medicine (2015). doi:10.1016/S2213-2600(15)00029-6
  5. Travis, W. D. et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 8, 381–5 (2011).
  6. Pelosi, G. et al. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol 6, 1039–49 (2011).
  7. Thunnissen, E. et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 76, 1–18 (2012).
  8. Leighl, N. B. et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J. Clin. Oncol. 32, 3673–9 (2014).
  9. Gahr et al. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. British journal of cancer 109, 1821–8 (2013).
  10. Lee, C. K. et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J. Natl. Cancer Inst. 105, 595–605 (2013).
  11. Piotrowska, Z. & Sequist, L. V. Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options. Cancer J 21, 371–7 (2015).
  12. Bergethon, K. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863–70 (2012).
  13. Brahmer, J. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med. 373, 123–35 (2015).
  14. Kerr, K. M. et al. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J Thorac Oncol 10, 985–9 (2015).

Die medikamentöse Therapie

M. Steins, Heidelberg (S. 16)

 

  1. Goeckenjan G, Sitter H, Thomas M et al.: Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft. Pneumologie 2010, 64 (Suppl.): S23-S155
  2. Vansteenkiste J, Crinò L, Dooms C et al.: 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 2014, 25: 1462-1474
  3. Eberhardt WE, De Ruysscher D, Weder W et al.: 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol 2015, 26: 1573-1588
  4. Reck M, Popat S, Reinmuth N et al.: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014, 25 (Suppl 3): iii27-39
  5. Besse B, Adjei A, Baas P et al.: 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol 2014, 25: 1475-1484
  6. Masters GA, Temin S, Azzoli CG et al.: Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015, 33: 3488-3515
  7. Reck M, Kaiser R, Mellemgaard A et al.: Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014, 15: 143-155
  8. Brahmer J, Reckamp KL, Baas P et al.: Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015, 373: 123-135
  9. Taube JM, Klein A, Brahmer JR et al.: Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014, 20: 5064-5074
  10. Mok TS, Wu YL, Thongprasert S et al.: Gefitinib or carboplatin/paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2007, 361: 947-957
  11. Rosell R, Carcereny E, Gervais R et al. on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie and the Associazione Italiana Oncologia Toracica: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13: 239-246
  12. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31: 3327-3334
  13. Wu YL, Zhou C, Hu CP et al.: Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014, 15: 213-222
  14. Greig SL: Osmertinib: First Global Approval. Drugs 2016, Epub ahead of print
  15. Camidge DR, Bang YJ, Kwak EL et al.: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13: 1011-1019
  16. Shaw AT, Kim DW, Mehra R et al.: Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014, 370: 1189-1197

Die Chirurgie des Lungenkarzinoms

H. Hoffmann, Heidelberg (S. 22)

 

  1. Krebs in Deutschland 2011/2012. 10. Auflage. Berlin: Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.(Hrsg); 2015
  2. Howington JA, Blum MG, Chang AC et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: e278S-e313S
  3. von Meyenfeldt EM, Gooiker GA, van GW et al. The relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: a systematic review and meta-analysis. JThoracOncol 2012; 7: 1170-1178
  4. Jett JR, Schild SE, Kesler KA et al. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: e400S-e419S
  5. Nakamura H, Kawasaki N, Taguchi M et al. Survival following lobectomy vs limited resection for stage I lung cancer: a meta-analysis. BrJCancer 2005; 92: 1033-1037
  6. Okada M, Koike T, Higashiyama M et al. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. JThoracCardiovascSurg 2006; 132: 769-775
  7. Cao C, Gupta S, Chandrakumar D et al. Meta-analysis of intentional sublobar resections versus lobectomy for early stage non-small cell lung cancer. AnnCardiothoracSurg 2014; 3: 134-141
  8. Nakamura K, Saji H, Nakajima R et al. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). JpnJClinOncol 2010; 40: 271-274
  9. Yan TD, Black D, Bannon PG et al. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. JClinOncol 2009; 27: 2553-2562
  10. Goeckenjan G, Sitter H, Thomas M et al. Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie 2011; 65: 39-59
  11. Robinson LA, Ruckdeschel JC, Wagner H, Jr. et al. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132: 243S-265S
  12. van Meerbeeck JP, Kramer GW, Van Schil PE et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. JNatlCancer Inst 2007; 99: 442-450
  13. Eberhardt WE, Pottgen C, Gauler TC et al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol 2015; 33: 4194-4201
  14. Albain KS, Swann RS, Rusch VW et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379-386
  15. Hauswald H, Rieken S, Dienemann HC et al. Ion therapy within the trimodal management of superior sulcus tumors: the INKA trial. BMC Cancer 2015; 15: 192
  16. Goldstraw P, Chansky K, Crowley J et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11: 39-51

Moderne Strahlentherapie des Lungenkarzinoms

S. Gerum, München (S. 30)

 

  1. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). GLOBOCAN 2008 v2. 0. Cancer incidence and mortality worldwide: IARC Cancer Base, (10).
  2. Goeckenjan, G., Sitter, H., Thomas, M., Branscheid, D., Flentje, M., Griesinger, F., & Kauczor, H. U. (2011). Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer. Pneumologie, 65(1), 39.
  3. Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R.,  ... & International Association for the Study of Lung Cancer International Staging Committee. (2007). The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. Journal of thoracic oncology, 2(8), 706-714.
  4. Marnitz S, Stuschke M, Bohsung J, Moys A, Reng I, Wurm R, Budach V. Intraindividual comparison of conventional three-dimensional radiotherapy and intensity modulated radiotherapy in the therapy of locally advanced non-small cell lung cancer a planning study. Strahlenther Onkol. 2002 Nov;178(11):651-8
  5. Selek U, Bölükba?? Y, Welsh JW, Topkan E. Intensity-Modulated Radiotherapy versus 3-Dimensional Conformal Radiotherapy Strategies for Locally Advanced Non-Small-Cell Lung Cancer. Balkan Med J. 2014 Dec; 31(4):286-94. doi: 10.5152/balkanmedj.2014.14529. Epub 2014 Sep 13. Review.
  6. De Ruysscher, D., Faivre-Finn, C., Nestle, U., Hurkmans, C. W., Le Péchoux, C., Price, A., & Senan, S. (2010). European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. Journal of Clinical Oncology, 28(36), 5301-5310.
  7. Burdett S, Stewart L, PORT Meta-analysis Group. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer 2005;47:81-3.
  8. Lally BE, Zelterman D, Colasanto M, Haffty BG, Detterbeck FC, Wilson LD. (2006) Postoperative Radiotherapy for Stage II or III Non-Small-Cell Lung Cancer Using the Surveillance, Epidemology, and End Results Database. J Clin Oncol 24:2998-3006
  9. Douillard, J. Y., Rosell, R., Delena, M., Legroumellec, A., Torres, A., & Carpagnano, F. (2005, June). ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (Stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. In ASCO Annual Meeting Proceedings (Vol. 23, No. 16_suppl, p. 7013)
  10. Guckenberger, M., Andratschke, N., Alheit, H., Holy, R., Moustakis, C., Nestle, U., & Sauer, O. (2014). Definition of stereotactic body radiotherapy. Principles and practice for the treatment of stage I non-small cell lung cancer. Strahlentherapie und Onkologie, 190(1), 26-33.
  11. Lindberg, K., Nyman, J., Riesenfeld Källskog, V., Hoyer, M., Lund, J. Å., Lax, I., ... & Lewensohn, R. (2015). Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT-the Nordic experience. Acta Oncologica, (0), 1-9.
  12. Roesch, J., Andratschke, N., & Guckenberger, M. (2014). SBRT in operable early stage lung cancer patients. Translational Lung Cancer Research, 3(4), 212.
  13. Guckenberger M, Allgäuer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol. 2013 Aug;8(8):1050-8. doi: 10.1097/JTO.0b013e318293dc45
  14. Onishi, H., Araki, T., Shirato, H., Nagata, Y., Hiraoka, M., Gomi, K., ... & Yamada, K. (2004). Stereotactic hypofractionated high?dose irradiation for stage I nonsmall cell lung carcinoma. Cancer, 101(7), 1623-1631.
  15. Shirvani, S. M., Jiang, J., Chang, J. Y., Welsh, J. W., Gomez, D. R., Swisher, S., ... & Smith, B. D. (2012). Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. International Journal of Radiation Oncology* Biology* Physics, 84(5), 1060-1070.
  16. Onishi, H., & Araki, T. (2013). Stereotactic body radiation therapy for stage I non-small-cell lung cancer: a historical overview of clinical studies. Japanese journal of clinical oncology, 43(4), 345-350.
  17. Timmerman, R., Paulus, R., Galvin, J., Michalski, J., Straube, W., Bradley, J., ... & Choy, H. (2010). Stereotactic body radiation therapy for inoperable early stage lung cancer. Jama, 303(11), 1070-1076.
  18. Timmerman, R., McGarry, R., Yiannoutsos, C., Papiez, L., Tudor, K., DeLuca, J., ... & Fletcher, J. (2006). Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. Journal of clinical oncology, 24(30), 4833-4839.
  19. Fakiris, A. J., McGarry, R. C., Yiannoutsos, C. T., Papiez, L., Williams, M., Henderson, M. A., & Timmerman, R. (2009). Stereotactic body radiation therapy for early-stage non–small-cell lung carcinoma: four-year results of a prospective phase II study. International Journal of Radiation Oncology* Biology* Physics, 75(3), 677-682.
  20. Chang, J. Y., Senan, S., Paul, M. A., Mehran, R. J., Louie, A. V., Balter, P., ... & Roth, J. A. (2015). Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet Oncology.
  21. Chang, J. Y., Liu, Y. H., Zhu, Z., Welsh, J. W., Gomez, D. R., Komaki, R., ... & Swisher, S. G. (2013). Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer, 119(18), 3402-3410.
  22. Guckenberger, M., Kestin, L. L., Hope, A. J., Belderbos, J., Werner-Wasik, M., Yan, D., ... & Grills, I. S. (2012). Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer?. Journal of Thoracic Oncology, 7(3), 542-551.
  23. Stanic, S., Paulus, R., Timmerman, R. D., Michalski, J. M., Barriger, R. B., Bezjak, A., ... & Bradley, J. (2014). No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early-stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. International Journal of Radiation Oncology* Biology* Physics, 88(5), 1092-1099.
  24. Chang JY, Bezjak A, Mornex F; IASLC Advanced Radiation Technology Committee. Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. J Thorac Oncol. 2015 Apr;10(4):577-85. doi: 10.1097/JTO.0000000000000453. Review
  25. Adebahr, S., Collette, S., Shash, E., Lambrecht, M., Le Pechoux, C., Faivre-Finn, C., ... & Nestle, U. (2015). LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. The British journal of radiology, 88(1051), 20150036.
  26. Baas P et al. Chemoradiationtherapy in non small cell lung cancer; Curr Opin Oncol 2011; 23 (2): 140 -9.
  27. Wurstbauer K, Weise H, …et al.: Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses ? 80 Gy in standard fractionation. Strahlenther Onkol. 2010 Oct;186(10):551-7. doi: 10.1007/s00066-010-2108-3. Epub 2010 Sep 30.
  28. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005;63:324–33
  29. Rengan R, Rosenzweig K, Venkatraman E, et al. Improved local control with higher doses of radiation in large-volume stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2004;60:741–7.
  30. Le Chevalier, T., Arriagada, R., Quoix, E., Ruffle, P., Martin, M., Tarayre, M., ... & Laplanche, A. (1991). Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. Journal of the National Cancer Institute, 83(6), 417-423.
  31. Dillman, R. O., Seagren, S. L., Propert, K. J., Guerra, J., Eaton, W. L., Perry, M. C., ... & Green, M. R. (1990). A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. New England Journal of Medicine, 323(14), 940-945.
  32. Furuse, K., Fukuoka, M., Kawahara, M., Nishikawa, H., Takada, Y., Kudoh, S., ... & Ariyoshi, Y. (1999). Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non–small-cell lung cancer. Journal of Clinical Oncology, 17(9), 2692-2692.
  33. Huber RM, Flentje M, Schmidt M, Pöllinger B, Gosse H, Willner J, Ulm K, Bronchial Carcinoma Therapy Group (2006) Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small cell lung cancer: Study CTRT 99/97 by the Bronchial Carcinoma Therapy Group. J ClinOncol 24(27): 4397-4404
  34. Hanna NH, Neubauer M, Ansari R, et al.: (2007) Phase III trial of Cisplatin (P) plus Etoposid (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small-cell lung cancer (NSCLC): HOG LUN 01.24/USO-023, J ClinOncol 25:7512
  35. Vokes EE, Herndon JE 2nd et al.: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lungcancer: Cancer and Leukemia Group B. J Clin Oncol. 2007 May 1;25(13):1698-704. Epub 2007 Apr 2.
  36. Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, Welter S, Budach W, Spengler W, Kimmich M, Fischer B, Schmidberger H, De Ruysscher D, Belka C, Cordes S, Hepp R, Lütke-Brintrup D, Lehmann N, Schuler M, Jöckel KH, Stamatis G, Stuschke M Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients WithResectable Stage IIIA(N2) and Selected IIIB Non-Small Cell Lung Cancer After Induction Chemotherapy andConcurrent Chemoradiotherapy (ESPATUE). J Clin Oncol. 2015 Dec 10;33(35):4194-201. doi: 10.1200/JCO.2015.62.6812. Epub 2015 Nov 
  37. Eberhardt WEE, Gauler TC, Pöttgen C, Friedel G, Veit S, Heinrich V, et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with operable stage IIIA(N2)/selected IIIB non-small cell lung cancer following induction chemotherapy and concurrent chemoradiotherapy (ESPATUE) J Clin Oncol. 2014;32
  38. Pöttgen, C., Eberhardt, W., Graupner, B., Theegarten, D., Gauler, T., Freitag, L., ... & Stuschke, M. (2013). Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation. European Journal of Cancer, 49(9), 2107-2115.
  39. Eberhardt, W. E. E., Gauler, T. C., LePechoux, C., Stamatis, G., Bildat, S., Krbek, T., ... & Poettgen, C. (2013). 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)—A multicenter phase-II trial (CISTAXOL). Lung Cancer, 82(1), 83-89.
  40. Marra A, Eberhardt W, Pöttgen C, Theegarten D, Korfee S, Gauler T, Stuschke M, Stamatis G. (2007) Induction chemotherapy, concurrent chemoradiation and surgery for Pancoast tumour. EurRespir J.  Jan;29(1):117-26.
  41. Rusch VW, Giroux DJ, Kraut MJ et al (2007) Induction chemordiation  and surgical resection for superior sulcus non-small-cell lung carcinomas: long term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160) J Clin Oncol 25:313-318
  42. Johnson, B. E., Grayson, J., Makuch, R. W., Linnoila, R. I., Anderson, M. J., Cohen, M. H., ... & Ihde, D. C. (1990). Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Journal of Clinical Oncology, 8(3), 396-401.
  43. Warde, P., & Payne, D. (1992). Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. Journal of Clinical Oncology, 10(6), 890-895.
  44. Pignon, J. P., Arriagada, R., Ihde, D. C., Johnson, D. H., Perry, M. C., Souhami, R. L., ... & Wagner, H. (1992). A meta-analysis of thoracic radiotherapy for small-cell lung cancer. New England Journal of Medicine, 327(23), 1618-1624.
  45. Fried, D. B., Morris, D. E., Poole, C., Rosenman, J. G., Halle, J. S., Detterbeck, F. C., ... & Socinski, M. A. (2004). Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. Journal of clinical oncology, 22(23), 4837-4845.
  46. Pijls-Johannesma, M., De Ruysscher, D., Rutten, I., Vansteenkiste, J., & Lambin, P. (2004). Early versus late chest radiotherapy for limited stage small cell lung cancer: a systematic review and meta-analysis. Radiotherapy and Oncology, 73, S164-S164.
  47. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006;24(7):1057-063)
  48. Turrisi, A. T., Kim, K., Blum, R., Sause, W. T., Livingston, R. B., Komaki, R., ... & Johnson, D. H. (1999). Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. New England Journal of Medicine, 340(4), 265-271.
  49. Jeremic, B., Shibamoto, Y., Nikolic, N., Milicic, B., Milisavljevic, S., Dagovic, A., ... & Radosavljevic-Asic, G. (1999). Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. Journal of clinical oncology, 17(7), 2092-2092.
  50. Slotman, B. J., van Tinteren, H., Praag, J. O., Knegjens, J. L., El Sharouni, S. Y., Hatton, M., ... & Senan, S. (2015). Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. The Lancet, 385(9962), 36-42.
  51. Kristjansen, P. E., & Kristensen, C. A. (1993). The role of prophylactic cranial irradiation in the management of small cell lung cancer. Cancer treatment reviews, 19(1), 3-16.
  52. Arriagada, R., Le Chevalier, T., Riviere, A., Chomy, P., Monnet, I., Bardet, E., ... & Laplanche, A. (2002). Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients. Annals of oncology, 13(5), 748-754.
  53. Patel, S., Macdonald, O. K., & Suntharalingam, M. (2009). Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer, 115(4), 842-850.
  54. Sas-Korczy?ska, B., Korzeniowski, S., & Wójcik, E. (2010). Comparison of the effectiveness of “late” and “early” prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. Strahlentherapie und Onkologie, 186(6), 315-319.
  55. Slotman, B. J., Mauer, M. E., Bottomley, A., Faivre-Finn, C., Kramer, G. W., Rankin, E. M., ... & Senan, S. (2009). Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms—results of an international phase III randomized controlled trial by the EORTC radiation oncology and lung cancer groups. Journal of Clinical Oncology, 27(1), 78-84.
  56. Le Pechoux C, Dunant A, Senan S et al (2009) Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy: a randomized clinical trial. Lancet Oncol 10: 467–474
  57. Aupérin, A., Arriagada, R., Pignon, J. P., Le Péchoux, C., Gregor, A., Stephens, R. J., ... & Aisner, J. (1999). Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. New England Journal of Medicine, 341(7), 476-484.